US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NeOnc Technologies Holdings

8.77

-0.4950-5.35%

Volume:47.17K

Turnover:429.59K

Market Cap:198.90M

PE:-3.39

High:9.40

Open:9.16

Low:8.63

Close:9.26

52wk High:25.00

52wk Low:3.20

Shares:22.69M

Float Shares:8.27M

Volume Ratio:0.90

T/O Rate:0.57%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.5859

EPS(LYR):-0.6900

ROE:--

ROA:-853.56%

PB:-16.84

PE(LYR):-12.70

Loading ...

Overview Company News Filings

NeOnc Technologies files to sell 2.95M shares of common stock for holders

NeOnc to Raise Up to $16 Million Through Private Placement

MT Newswires Live

NeOnc Technologies secures strategic PIPE investment from Cinctive Capital

Neonc Technologies Secures Strategic Pipe Investment Led by $10 Million Investment From Cinctive Capital Management

THOMSON REUTERS

Neonc Technologies Holdings Inc - Pipe Investment to Result in $16 Mln Gross Proceeds

THOMSON REUTERS

Press Release: NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management

Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings

BRIEF-NeOnc Technologies Holdings Files Prospectus For Offer & Sale From Time To Time By Selling Stockholders For Up To 111,732 Shares Of Common Stock

Neonc Technologies Holdings: Files Prospectus for Offer & Sale From Time to Time by Selling Stockholders for up to 111,732 Shares of Common Stock

THOMSON REUTERS

NeOnc Technologies Reports Promising Remission Results for Intranasal NEO100 in Recurrent IDH1-Mutant Astrocytoma

NeOnc Technologies Reports Promising Remission Rates in Phase 2 Trial of Intranasal NEO100 for Recurrent IDH1-Mutant Gliomas

NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors

NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors

Neonc Technologies Holdings Inc. Files Initial Beneficial Ownership Statement for Director Ming-Fu (Alan) Chiang

Chief Clinical Officer Yousha Neman-Ebrahim Acquires Common Shares of Neonc Technologies Holdings Inc

NeOnc Technologies Q3 EPS $(0.45)

NeOnc Technologies Holdings reports Q3 net loss of $8.6 million on higher expenses

Neonc Technologies Holdings Inc - Reports Q3 Net Loss of $8.6 Mln or $0.45 per Share

THOMSON REUTERS

NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update

NeOnc Technologies Completes Enrollment in Phase 2a Trial for NEO100 in Recurrent High-Grade Glioma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NTHI/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTHI","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","market":"US","secType":"STK","nameCN":"NeOnc Technologies Holdings","latestPrice":8.765,"timestamp":1771446400502,"preClose":9.26,"halted":0,"volume":47168,"delay":0,"changeRate":-0.05345572354211655,"floatShares":8266400,"shares":22692159,"eps":-2.5859,"marketStatus":"Trading","change":-0.495,"latestTime":"02-18 15:27:12 EST","open":9.16,"high":9.4,"low":8.625,"amount":429593.03129600006,"amplitude":0.083693,"askPrice":8.87,"askSize":100,"bidPrice":8.7,"bidSize":50,"shortable":0,"etf":0,"ttmEps":-2.5859,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1771448400000},"marketStatusCode":2,"adr":0,"listingDate":1711512000000,"exchange":"NASDAQ","adjPreClose":9.26,"postHourTrading":{"tag":"盘后","latestPrice":9.26,"preClose":9.26,"latestTime":"16:10 EST","volume":3,"amount":27.78,"timestamp":1771362604721,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.898899},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTHI\",,,,,undefined,":{"symbol":"NTHI","floatShares":8266400,"roa":"-853.56%","roe":"--","lyrEps":-0.69,"volumeRatio":0.898899,"shares":22692159,"dividePrice":0,"high":9.4,"amplitude":0.083693,"preClose":9.26,"low":8.625,"week52Low":3.2,"pbRate":"-16.84","psRate":"3315.50","week52High":25,"institutionHeld":0,"latestPrice":8.765,"committee":-0.333333,"eps":-2.5859,"divideRate":0,"volume":47168,"delay":0,"ttmEps":-2.5859,"open":9.16,"prevYearClose":8.27,"prevWeekClose":10.24,"prevMonthClose":9.27,"prevQuarterClose":8.27,"fiveDayClose":10.72,"twentyDayClose":8.36,"sixtyDayClose":6.73},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTHI\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"NTHI","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-18","symbol":"NTHI","fiscalQuarterEnding":"2025/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1755489600000,"reportTimeType":"","actualEps":-0.3}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTHI\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTHI\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NTHI\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NTHI","date":"2026-02-17","current":-3.389536,"percent":0.34375,"low":-26.074295,"twenty":-5.144166,"median":-3.570116,"eighty":-2.398993,"high":-1.357276,"avg":-4.711997,"sd":3.908477,"marketCap":199416862},"quantilePoints":[{"date":"2024-03-28","current":-18.899455,"twenty":-18.899455,"median":-18.899455,"eighty":-18.899455,"marketCap":282000000},{"date":"2025-03-28","current":-18.905834,"twenty":-19.009816,"median":-18.905834,"eighty":-18.902007,"marketCap":224950380},{"date":"2025-04-04","current":-15.093157,"twenty":-20.260752,"median":-18.902645,"eighty":-16.151884,"marketCap":179585386},{"date":"2025-04-11","current":-14.179375,"twenty":-19.504518,"median":-17.739974,"eighty":-15.124667,"marketCap":168712785},{"date":"2025-04-17","current":-11.028403,"twenty":-19.044476,"median":-15.392499,"eighty":-12.855967,"marketCap":131221055},{"date":"2025-04-25","current":-9.437162,"twenty":-18.904558,"median":-14.667776,"eighty":-10.965384,"marketCap":112287731},{"date":"2025-05-02","current":-8.444606,"twenty":-18.667559,"median":-12.525115,"eighty":-9.437162,"marketCap":100477836},{"date":"2025-05-09","current":-10.398208,"twenty":-17.342951,"median":-11.028403,"eighty":-9.33318,"marketCap":123722709},{"date":"2025-05-16","current":-2.933338,"twenty":-15.682389,"median":-10.398208,"eighty":-8.444606,"marketCap":137753858},{"date":"2025-05-23","current":-2.969802,"twenty":-15.348385,"median":-9.44504,"eighty":-3.015179,"marketCap":139466268},{"date":"2025-05-30","current":-2.99006,"twenty":-15.171931,"median":-9.437162,"eighty":-2.969802,"marketCap":140417606},{"date":"2025-06-06","current":-3.034627,"twenty":-15.093157,"median":-9.311123,"eighty":-2.969802,"marketCap":142510552},{"date":"2025-06-13","current":-2.593006,"twenty":-14.242395,"median":-8.476116,"eighty":-2.937389,"marketCap":121771366},{"date":"2025-06-20","current":-1.928548,"twenty":-14.191979,"median":-7.853798,"eighty":-2.929004,"marketCap":90567453},{"date":"2025-06-27","current":-1.616577,"twenty":-12.855967,"median":-3.034627,"eighty":-2.802066,"marketCap":75916836},{"date":"2025-07-03","current":-2.362066,"twenty":-12.222621,"median":-3.010317,"eighty":-2.532985,"marketCap":110926104},{"date":"2025-07-11","current":-1.977167,"twenty":-11.425425,"median":-2.998163,"eighty":-2.362066,"marketCap":92850666},{"date":"2025-07-18","current":-1.786743,"twenty":-11.028403,"median":-2.99006,"eighty":-2.222692,"marketCap":83908082},{"date":"2025-07-25","current":-1.904238,"twenty":-10.981139,"median":-2.959854,"eighty":-1.949616,"marketCap":89425847},{"date":"2025-08-01","current":-1.98527,"twenty":-10.618776,"median":-2.937389,"eighty":-1.970684,"marketCap":93231202},{"date":"2025-08-08","current":-1.944754,"twenty":-10.133526,"median":-2.931642,"eighty":-1.939892,"marketCap":91328524},{"date":"2025-08-15","current":-2.102765,"twenty":-9.654579,"median":-2.909028,"eighty":-1.943134,"marketCap":98748967},{"date":"2025-08-22","current":-2.604584,"twenty":-9.443464,"median":-2.799635,"eighty":-1.954478,"marketCap":110548110},{"date":"2025-08-29","current":-3.15078,"twenty":-9.437162,"median":-2.795584,"eighty":-1.970684,"marketCap":133730643},{"date":"2025-09-05","current":-3.371966,"twenty":-9.437162,"median":-2.876616,"eighty":-1.980408,"marketCap":143118611},{"date":"2025-09-12","current":-4.405675,"twenty":-9.43086,"median":-2.918386,"eighty":-1.98527,"marketCap":186992991},{"date":"2025-09-19","current":-5.457439,"twenty":-9.377293,"median":-2.933338,"eighty":-1.993373,"marketCap":231633736},{"date":"2025-09-26","current":-4.681029,"twenty":-9.292217,"median":-2.939656,"eighty":-2.005528,"marketCap":198680053},{"date":"2025-10-03","current":-5.141458,"twenty":-8.961365,"median":-2.969802,"eighty":-2.008769,"marketCap":218222354},{"date":"2025-10-10","current":-5.407785,"twenty":-8.482417,"median":-2.99006,"eighty":-2.016872,"marketCap":229526233},{"date":"2025-10-17","current":-4.730683,"twenty":-8.444606,"median":-3.002214,"eighty":-2.039561,"marketCap":200787556},{"date":"2025-10-24","current":-3.769199,"twenty":-7.97196,"median":-3.022472,"eighty":-2.067922,"marketCap":159978635},{"date":"2025-10-31","current":-4.590749,"twenty":-7.105442,"median":-3.15078,"eighty":-2.071973,"marketCap":194848230},{"date":"2025-11-07","current":-4.446301,"twenty":-6.304447,"median":-3.298614,"eighty":-2.085748,"marketCap":188717312},{"date":"2025-11-14","current":-4.053582,"twenty":-5.457439,"median":-3.638293,"eighty":-2.120592,"marketCap":172048879},{"date":"2025-11-21","current":-2.32457,"twenty":-5.457439,"median":-3.482559,"eighty":-2.150574,"marketCap":113613569},{"date":"2025-11-28","current":-3.566132,"twenty":-5.449314,"median":-3.447134,"eighty":-2.162729,"marketCap":174295011},{"date":"2025-12-05","current":-3.725512,"twenty":-5.41591,"median":-3.522302,"eighty":-2.193521,"marketCap":182084733},{"date":"2025-12-12","current":-3.733481,"twenty":-5.411396,"median":-3.568124,"eighty":-2.214589,"marketCap":182474219},{"date":"2025-12-19","current":-2.797122,"twenty":-5.405979,"median":-3.570116,"eighty":-2.278603,"marketCap":136709607},{"date":"2025-12-26","current":-3.327062,"twenty":-5.398757,"median":-3.566132,"eighty":-2.301292,"marketCap":162610430},{"date":"2026-01-02","current":-3.295186,"twenty":-5.391535,"median":-3.474488,"eighty":-2.319914,"marketCap":161052485},{"date":"2026-01-09","current":-3.916768,"twenty":-5.368062,"median":-3.548202,"eighty":-2.33285,"marketCap":191432398},{"date":"2026-01-16","current":-3.466519,"twenty":-5.344589,"median":-3.566132,"eighty":-2.344813,"marketCap":169426436},{"date":"2026-01-23","current":-3.486442,"twenty":-5.296741,"median":-3.53824,"eighty":-2.348861,"marketCap":170400151},{"date":"2026-01-30","current":-3.486442,"twenty":-5.229933,"median":-3.552186,"eighty":-2.357204,"marketCap":170400151},{"date":"2026-02-06","current":-3.681683,"twenty":-5.174862,"median":-3.566132,"eighty":-2.362066,"marketCap":179942559},{"date":"2026-02-13","current":-4.169784,"twenty":-5.146875,"median":-3.570116,"eighty":-2.389761,"marketCap":203798580},{"date":"2026-02-17","current":-4.080133,"twenty":-5.144166,"median":-3.570116,"eighty":-2.398993,"marketCap":199416862}],"updateTime":1771446432828},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTHI\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609514440","title":"NeOnc Technologies files to sell 2.95M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514440","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609514440?lang=en_us&edition=fundamental","pubTime":"2026-02-07 05:55","pubTimestamp":1770414914,"startTime":"0","endTime":"0","summary":"16:50 EST NeOnc Technologies (NTHI) files to sell 2.95M shares of common stock for holders Published first on TheFly – the ultimate source for real...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-files-to-sell-2-95m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-files-to-sell-2-95m-shares-of-common-stock-for-holders-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2607047857","title":"NeOnc to Raise Up to $16 Million Through Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2607047857","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607047857?lang=en_us&edition=fundamental","pubTime":"2026-01-30 23:28","pubTimestamp":1769786932,"startTime":"0","endTime":"0","summary":"NeOnc Technologies  said Friday it has struck a deal to sell up to about 2.2 million shares and five-year warrants to buy up to some 2.2 million shares at $7.20 per share and warrant to investors.The warrants have an exercise price of $9.00 per share, it said.The company said the private placement to raise up to about $16 million is led by a $10 million investment by Cinctive Capital Management, a multi-strategy investment firm.NeOnc said it plans to use the net proceeds to repay debt and for working capital and corporate purposes.Shares were up over 2% in recent trading.Price: 8.95, Change: +0.20, Percent Change: +2.29","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2607049713","title":"NeOnc Technologies secures strategic PIPE investment from Cinctive Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2607049713","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607049713?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:17","pubTimestamp":1769782631,"startTime":"0","endTime":"0","summary":"NeOnc Technologies (NTHI) announced that it has entered into a securities purchase agreement for a private investment in public equity for the purc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neonc-technologies-secures-strategic-pipe-investment-from-cinctive-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neonc-technologies-secures-strategic-pipe-investment-from-cinctive-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NTHI","PIPE"],"gpt_icon":0},{"id":"2607212046","title":"Neonc Technologies Secures Strategic Pipe Investment Led by $10 Million Investment From Cinctive Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2607212046","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607212046?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:00","pubTimestamp":1769781601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA9FHG54:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2607046252","title":"Neonc Technologies Holdings Inc - Pipe Investment to Result in $16 Mln Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2607046252","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607046252?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:00","pubTimestamp":1769781601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nTUA9FHG54:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2607461060","title":"Press Release: NeOnc Technologies Secures Strategic PIPE Investment led by $10 Million Investment from Cinctive Capital Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2607461060","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607461060?lang=en_us&edition=fundamental","pubTime":"2026-01-30 22:00","pubTimestamp":1769781600,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., Jan. 30, 2026  -- NeOnc Technologies Holdings, Inc.  , a multi-Phase 2 clinical-stage biopharmaceutical company developing novel therapies for central nervous system  cancers, today announced that it has entered into a securities purchase agreement for a private investment in public equity  for the purchase and sale of up to 2,222,222 shares of common stock and five-year warrants to purchase up to 2,222,222 shares of common stock at a per share exercise price of $9.00 at a combined purchase price of $7.20, that is expected to result in gross proceeds of up to approximately $16 million to the Company. NeOnc currently intends to use the net proceeds from the offering for repayment of indebtedness, and for working capital and corporate purposes.Amir F. Heshmatpour, Executive Chairman, President & CEO of NeOnc Technologies Holdings, Inc., stated: \"This strategic investment from a firm of Cinctive Capital's caliber validates our technological approach and the potential of","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","PIPE","TM","NTHI","BK4099","03160","BK4585","BK4588","BK4604","BK4135","IND","BK4007","BK4555"],"gpt_icon":0},{"id":"2602300316","title":"Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300316","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602300316?lang=en_us&edition=fundamental","pubTime":"2026-01-10 08:33","pubTimestamp":1768005183,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via Newsfile  on January 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL89mHtk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2593446479","title":"BRIEF-NeOnc Technologies Holdings Files Prospectus For  Offer & Sale From Time To Time By Selling Stockholders For Up To 111,732 Shares Of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2593446479","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593446479?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:53","pubTimestamp":1766530403,"startTime":"0","endTime":"0","summary":"BRIEF-NeOnc Technologies Holdings Files Prospectus For  Offer & Sale From Time To Time By Selling Stockholders For Up To 111,732 Shares Of Common StockDec 23  - Neonc Technologies Holdings Inc NTHI.O:NEONC TECHNOLOGIES HOLDINGS: FILES PROSPECTUS FOR  OFFER & SALE FROM TIME TO TIME BY SELLING STOCKHOLDERS FOR UP TO 111,732 SHARES OF COMMON STOCKSource text: [ID:n0001829126-25-010285]Further company coverage: NTHI.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0RU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2593121445","title":"Neonc Technologies Holdings: Files Prospectus for  Offer & Sale From Time to Time by Selling Stockholders for up to 111,732 Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2593121445","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593121445?lang=en_us&edition=fundamental","pubTime":"2025-12-24 06:09","pubTimestamp":1766527743,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nFWN3XT0RU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2592943982","title":"NeOnc Technologies Reports Promising Remission Results for Intranasal NEO100 in Recurrent IDH1-Mutant Astrocytoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2592943982","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592943982?lang=en_us&edition=fundamental","pubTime":"2025-12-18 05:06","pubTimestamp":1766005585,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced updated clinical results from its ongoing Phase 1/2a and compassionate-use experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The expanded clinical cohort now includes 25 patients, with updated results showing that intranasal NEO100 has resulted in radiographic remission in 6 of 25 patients (24%). This response rate is higher than the 8% typically reported with salvage therapies for recurrent high-grade gliomas. No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged dosing. The updated clinical results were presented in the company's announcement.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL2wLqZ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2591644953","title":"NeOnc Technologies Reports Promising Remission Rates in Phase 2 Trial of Intranasal NEO100 for Recurrent IDH1-Mutant Gliomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644953","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591644953?lang=en_us&edition=fundamental","pubTime":"2025-12-15 22:00","pubTimestamp":1765807246,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced updated clinical results from its ongoing Phase 1/2a and compassionate-use clinical experience evaluating intranasal NEO100 in patients with recurrent WHO Grade III/IV IDH1-mutant astrocytoma. The expanded clinical cohort now includes 25 patients, with results indicating significant radiographic remission in 6 of 25 patients (24%), which is higher than the 8% response rate typically reported with salvage therapies in recurrent high-grade gliomas. No significant toxicity has been observed with intranasal administration of NEO100, even with prolonged dosing. These updated results have already been presented by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Hol","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDL1KM3sP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","SG9999014021.USD","SG9999014039.USD","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","BK4007","BK4588","IE00BGHQF748.EUR","NDAQ","NTHI","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2589848365","title":"NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2589848365","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589848365?lang=en_us&edition=fundamental","pubTime":"2025-12-06 06:01","pubTimestamp":1764972089,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc.  announced newly published preclinical findings from a research collaboration at the University of Southern California. The study, now available on bioRxiv, indicates that the use of ultrasound enhances the therapeutic potency of NEO100 in treating primary and metastatic brain tumors. The research utilized an AI-driven, 3D-bioprinted methodology to rapidly generate patient-derived tumor organoids and demonstrated strong antitumor effects when NEO100 was combined with ultrasound. The results have already been presented through publication on bioRxiv.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nNDL60Dbs4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2588618773","title":"NeOnc Technologies Unveils AI-Driven Study Showing Ultrasound Boosts NEO100 Potency Against Brain Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2588618773","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588618773?lang=en_us&edition=fundamental","pubTime":"2025-12-01 22:00","pubTimestamp":1764597613,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc.  announced newly published preclinical findings from a research collaboration at the University of Southern California  demonstrating that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors. The study, available on bioRxiv, utilized an AI-driven, 3D-bioprinted platform to identify NEO100 as a promising agent for sonodynamic therapy. Validation studies on patient-derived tumor organoids showed increased antitumor activity when NEO100 was combined with focused ultrasound. The company indicated that these results support advancing NEO100 with focused ultrasound into future clinical trials across various brain tumor types. Results have already been presented in the published preclinical study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL8CvNwn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","NTHI","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","BK4007","BK4585","BK4112"],"gpt_icon":0},{"id":"2586141578","title":"Neonc Technologies Holdings Inc. Files Initial Beneficial Ownership Statement for Director Ming-Fu (Alan) Chiang","url":"https://stock-news.laohu8.com/highlight/detail?id=2586141578","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586141578?lang=en_us&edition=fundamental","pubTime":"2025-11-25 07:13","pubTimestamp":1764026025,"startTime":"0","endTime":"0","summary":"Neonc Technologies Holdings Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names Ming-Fu  Chiang as a director and the reporting beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7KY6d8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2586640415","title":"Chief Clinical Officer Yousha Neman-Ebrahim Acquires Common Shares of Neonc Technologies Holdings Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586640415","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586640415?lang=en_us&edition=fundamental","pubTime":"2025-11-25 06:47","pubTimestamp":1764024435,"startTime":"0","endTime":"0","summary":"Yousha Neman-Ebrahim, Chief Clinical Officer of Neonc Technologies Holdings Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 24, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL7PRqTZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Chief Clinical Officer Yousha Neman-Ebrahim Acquires Common Shares of Neonc Technologies Holdings Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2583668108","title":"NeOnc Technologies Q3 EPS $(0.45)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583668108","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583668108?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:04","pubTimestamp":1763154294,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Q3 EPS $(0.45)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48879667/neonc-technologies-q3-eps-0-45","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"NeOnc Technologies Q3 EPS $(0.45)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","BK4007"],"gpt_icon":0},{"id":"2583814256","title":"NeOnc Technologies Holdings reports Q3 net loss of $8.6 million on higher expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2583814256","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583814256?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154074,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. reported a net loss of $8.6 million, or $0.45 per diluted share, for the third quarter of 2025, compared to a net loss of $2.2 million, or $0.12 per diluted share, in the same period last year. General and administrative expenses increased to $903,000 from $244,000, while research and development expenses decreased to $715,000 from $957,000. During the period, the company advanced its NEO100 and NEO212 clinical programs, received $2.5 million in NIH STTR grants, expanded into the Middle East through new partnerships, and acquired advanced AI and 3D bioprinting intellectual property.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to gen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL6MdfQz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","NDAQ","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","NTHI","LU0314104364.USD","IE00B3QW5Z07.USD","BK4007","LU2095319765.USD"],"gpt_icon":0},{"id":"2583681415","title":"Neonc Technologies Holdings Inc - Reports Q3 Net Loss of $8.6 Mln or $0.45 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681415?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nTUA36SJFL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NTHI"],"gpt_icon":0},{"id":"2583682461","title":"NeOnc Technologies Holdings Reports Third Quarter 2025 Results and Provides Operational Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583682461","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583682461?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:01","pubTimestamp":1763154060,"startTime":"0","endTime":"0","summary":"CALABASAS, Calif., Nov.  14, 2025  (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering therapie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/14/3188596/0/en/NeOnc-Technologies-Holdings-Reports-Third-Quarter-2025-Results-and-Provides-Operational-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTHI","CNS","BK4007","BK4135"],"gpt_icon":0},{"id":"2583951595","title":"NeOnc Technologies Completes Enrollment in Phase 2a Trial for NEO100 in Recurrent High-Grade Glioma","url":"https://stock-news.laohu8.com/highlight/detail?id=2583951595","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583951595?lang=en_us&edition=fundamental","pubTime":"2025-11-13 22:00","pubTimestamp":1763042415,"startTime":"0","endTime":"0","summary":"NeOnc Technologies Holdings Inc. has announced the completion of patient enrollment in its Phase 2a clinical trial evaluating NEO100, a novel intranasal therapy, for the treatment of recurrent isocitrate dehydrogenase 1 -mutant high-grade glioma . The company previously presented positive results from a 24-patient cohort during an investor conference call on November 12, 2025. Preliminary data from the fully enrolled cohort are expected to be reported in the second quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neonc Technologies Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL8KpWkf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","BK4588","BK4112","NDAQ","BK4007","NTHI","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}]}}